Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 2Phase 2 2

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 3

Conditions

Neoplasms 3Ovarian Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumor, Unspecified, Adult 1Solid Tumor 1Prostatic Neoplasms 1Metastatic Castration Resistant Prostate Cancer 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Advanced Solid Tumors 1Advanced Solid Tumor 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × rucaparib × Clear all
NCT02740712 2023-06-09

DDI

pharmaand GmbH

Phase 1 Completed
17 enrolled
Tumor-Agnostic

Neoplasms

NCT03521037 2023-06-09

Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor

pharmaand GmbH

Phase 1 Completed
16 enrolled
Tumor-Agnostic

Neoplasms

NCT03954366 2023-06-08

Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives

pharmaand GmbH

Phase 1 Completed
36 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡